Low-Dose Psilocybin Food Microbes With Controlled Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing psilocybin are not suitable for creating food products due to high potency and instability, making it difficult to achieve safe, low-dose, and controllable levels for consumer consumption.
Innovation Solution
Development of beer, bread, and wine yeasts, as well as Lactobacillus, with controlled gene expression to produce low and predictable amounts of psilocybin, allowing for the creation of consumables with microdoses or sub-microdoses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If psilocybin is produced through traditional extraction or chemical synthesis methods, then sufficient psilocybin can be obtained, but the content is either too low to be commercially viable or the synthesis is complicated and expensive
Solution Approach 1:
The patent uses genetically modified yeast as an intermediary organism to produce psilocybin. The yeast cells are engineered with fungal genes (psaA, psaB, psiK, psiM) that enable them to convert tryptophan into psilocybin through a controlled metabolic pathway, serving as a biological mediator between simple substrates and the target compound
Solution Approach 2:
The patent controls psilocybin production by adjusting genetic parameters (promoter strength, gene expression levels) and environmental parameters (tryptophan concentration, cultivation conditions). This allows optimization of psilocybin yield while maintaining manufacturing simplicity and cost-effectiveness
2Reliability
If psilocin is synthesized or extracted, then the active compound is obtained, but it is relatively unstable in solution and readily forms degradation products
Solution Approach 1:
The patent produces psilocybin (the stable prodrug) rather than psilocin directly. Psilocybin serves as a stable intermediary that can be stored and transported without degradation, then converted to active psilocin in the body, avoiding the stability issues of direct psilocin production
Solution Approach 2:
The patent performs preliminary conversion of tryptophan to psilocybin within the yeast cells before the compound is extracted. This preliminary action creates the stable form that can then be isolated and stored, preventing degradation that would occur if psilocin were produced directly
3Quantity of substance
If high levels of psilocybin are produced in foodstuffs, then sufficient dosage is achieved, but consumer safety is compromised
Solution Approach 1:
The patent creates spatial and functional differentiation in psilocybin production. Different yeast strains with varying expression levels are used in different food products, allowing precise control of dosage. The genetic modification is localized to specific production lines rather than all food products
Solution Approach 2:
The patent uses controlled gene expression to produce partial levels of psilocybin (microdoses) rather than full therapeutic doses. This partial action achieves the desired effect while maintaining safety margins, using promoters and cultivation conditions that limit production to safe levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the production of foodstuffs with reliable, safe, and low-dose psilocybin levels, ensuring consumer safety and minimal impact on flavor profiles.
Implementation Method 1
Development of beer, bread, and wine yeasts, as well as Lactobacillus, with controlled gene expression to produce low and predictable amounts of psilocybin
Data Source
AI summary
Microbes are transformed with psilocybin genes under the control of weak or medium level promoter to make low levels of psilocybin therein. Low dose, microdose and sub-microdose foodstuff are then made with such microbes.